赛诺菲安万特 SNY 深 沪
等待开盘 12-20 09:30:00 美东时间
48.18
+0.190
+0.40%
华盛通- 最 高50.605
- 今 开47.71
- 成交量 194.09万股
- 最 低 46.97
- 昨 收 47.99
- 总市值 1217.51亿
- 52周最高 60.115
- 市盈率 静 16.48
- 换手率 0.08%
- 52周最低 44.6168
- 委 比 -11.89%
- 总股本 25.27亿
- 历史最高 60.115
- 量 比 0.65
- 振 幅 7.57%
- 历史最低 1.10
- 每 手 1
- 风险率 2.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sanofi Reaches Agreement With Trump Administration To Reduce Medicine Costs
Sanofi today announced an agreement with President Donald J. Trump's Administration to help ensure American patients have access to more affordable medicines while also supporting the role of the US in biopharmaceutical
今天 03:24
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms.
12-18 23:14
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Sanofi expands its partnership with Dren Bio in a deal featuring $100 million upfront and up to $1.7 billion tied to a next-generation autoimmune B-cell therapy.
12-16 02:10
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks
Sanofi said its Phase 3 PERSEUS trial of tolebrutinib missed the primary endpoint in PPMS, ending plans for regulatory filing.
12-15 20:52
Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs
Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for hemophilia and aTTP patients.
12-12 02:11
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks
U.S. regulators are reexamining infant RSV antibody treatments as safety questions surface, prompting new FDA scrutiny of products from major drugmakers.
12-10 00:30
Guggenheim Downgrades Sanofi to Neutral
Guggenheim analyst Seamus Fernandez downgrades Sanofi (NASDAQ:SNY) from Buy to Neutral.
12-09 20:16
Kymera Stock Smashes 52-Week High As New Pill Crushes Eczema Markers
Kymera Therapeutics released positive clinical results for KT-621 for atopic dermatitis and other allergic diseases.
12-08 22:54
Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe
Sanofi faces a surprise tax probe in France as Dupixent secures EU approval for treating chronic spontaneous urticaria.
11-26 02:30
Texas Attorney General Paxton Sues Big Pharma Companies Bristol-Myers Squibb And Sanofi For Making Billions While Harming Americans And Failing To Disclose Plavix's Ineffectiveness
https://www.texasattorneygeneral.gov/news/releases/attorney-general-paxton-sues-big-pharma-companies-bristol-myers-squibb-and-sanofi-making-billions
11-21 04:54
